Introduction
The CACNA1A gene on chromosome 19p13 encodes the pore-forming subunit of the P/Q-type voltage-gated calcium channel, which is expressed particularly abun-sodic symptoms [6] . Furthermore, our index patient and her mother, although harboring the same mutation, are differentially affected: The daughter suffered from episodic ataxia, hemiplegic migraine, and moderate progressive cerebellar ataxia with onset in her late 20s, whereas the mother had isolated severe progressive cerebellar ataxia with onset in her late 40s. Moreover, the two family members exhibited different patterns of cerebellar ocular motor deficiencies.
Case Reports

Case 1
Over the past 9 years, the 39-year-old woman has experienced several episodes of spontaneous acute vertigo, gait ataxia, and weakness. Attacks lasted a few minutes and occurred less than once a month. The patient described spinning and see-sawing sensations during the attacks exacerbated by head movement. There were no prodromal symptoms and no other otologic or neurologic symptoms during these episodes. Since adolescence, the patient had suffered from severe and frequent migraine headaches without aura, which decreased markedly in frequency and severity after the age of 30 years. In the past 3 years she has had two attacks, lasting 10-15 min, with sudden left-sided hemiparesis, paresthesia of the left leg, and dysarthria, without associated dizziness or headaches. She has noticed slowly progressive unsteadiness of gait for 2 years. Neurological examination revealed a moderate pancerebellar syndrome with prominent ocular motor signs ( table 1 ) . Laboratory testing showed positive serum paraneoplastic cerebellar antibodies (anti-Ri). Extensive search for neoplasia, however, did not reveal any signs of a primary tumor. Brain MRI showed mild midline cerebellar atrophy. Treatment with acetazolamide up to 750 mg/day for 3 months did not reduce the frequency of attacks, and had to be stopped because of continuous dizziness, increased gait difficulties, and generalized paresthesias. Treated with the calcium channel antagonist flunarizine 5 mg/day for 9 months, the patient has experienced no more attacks of dizziness or hemiplegic migraine, while the unsteadiness of gait at baseline remained stable.
Case 2
The 73-year-old mother reported progressive gait unsteadiness starting at age 48. Over the past 3 years she was unable to walk unaided. Increasing clumsiness of the upper limbs and slurred speech developed 5 years ago. She never experienced migraine headaches, dizziness or hemiparesis. Neurological examination revealed a severe pancerebellar syndrome with only mild ocular motor abnormalities ( table 1 ). Tendon reflexes were brisk and slightly accentuated on the left side. Plantar responses were flexor on the right side and extensor on the left side. Routine laboratory testing was normal. Testing for paraneoplastic cerebellar antibodies was negative. Cerebral MRI showed marked atrophy of cerebellar vermis and some isolated small supratentorial T 2 -hyperintensities, most probably reflecting chronic vascular lesions. Treatment with acetazolamide up to 750 mg for 3 months caused the unsteady gait to markedly worsen that the patient fell repeatedly. After cessation of acetazolamide, her clinical condition returned to baseline. Treatment with flunarizine for 9 months (5 mg/day) resulted in little change in the patient's condition.
Except for the deceased grandmother of our index patient, who suffered from gait unsteadiness and dizziness in advanced age, none of the mother's siblings nor the brother of the index patient suffers from neurological symptoms.
Ocular Motor Findings
Horizontal and vertical eye movements ( fig. 1 ) were recorded with magnetic search coils. Details of the search coil recordings are listed in the figure legend.
Molecular Analysis
We screened for polymorphisms in CACNA1A using denaturing high-performance liquid chromatography (dHPLC) followed by direct sequencing, as previously described [5] . Exon 32 showed an altered elution profile by dHPLC in the proband and her mother but not in 96 normal control subjects. Sequencing of exon 32 showed a single nucleotide change c 1 t at position 5250 of the coding sequence, predicting a change from arginine to tryptophan at codon 1668 in the putative S-4 voltage sensor in domain IV. 
Discussion
We report a family with the CACNA1A missense mutation R1668W. While our index patient had a particular phenotype with combined features of hemiplegic migraine, episodic ataxia, and progressive ataxia, her mother suffered from pure progressive cerebellar ataxia without episodic symptoms and without migraine.
A disease-causing role of the R1668W mutation in our patients is very likely, since this mutation has been previously described in a family with pure hemiplegic migraine and another with hemiplegic migraine and permanent cerebellar signs [6] , and screening for polymorphisms in CACNA1A was negative in 96 control subjects. Presumably, the mutation leads to altered channel kinematics since it predicts an amino acid exchange in the putative S-4 voltage sensor in domain IV of the P/Q-type voltage-gated calcium channel.
Our cases illustrate the broad clinical spectrum and variable symptomatology associated with CACNA1A mutations. This is in line with previous reports demonstrating phenotypic variability of CACNA1A mutations, hampering a simple genotype-phenotype correlation. Indeed, EA2 phenotypes are associated with nonsense and missense mutations as well as CAG-triplet repeat expansions [6, 7, 9] . On the other hand, CACNA1A missense mutations are also associated with severe progressive cerebellar ataxia with episodic vertigo and ataxia [10] . Additional genetic, for example the number of CAG repeats on the normal allele, and/or environmental factors must contribute to the phenotypic variability associated with distinct CACNA1A mutations.
This phenotypic diversity is reflected not only in the clinical but also in the ocular motor findings in the two affected family members. The index patient showed marked horizontal gaze-evoked and rebound nystagmus, whereas the mother exhibited square wave jerks and spontaneous downbeat nystagmus. We therefore speculate that, in the 2 patients, the R1668W mutation differentially alters the function of vestibulo-cerebellar structures, especially the flocculus. While gaze-evoked and rebound nystagmus indicates a failure of gaze-holding mechanisms, downbeat nystagmus suggests primarily a dysfunction of vertical gaze-velocity sensitive Purkinje cells [11] .
The finding of elevated anti-Ri antibodies in the index patient may be suspicious for paraneoplastic cerebellar degeneration, yet the patient did not manifest opsoclonus, myoclonus, or dystonia, symptoms which are often associated with anti-Ri antibodies [12] . Furthermore, the temporal progression of her symptoms is far less pronounced than what is typically found in paraneoplastic cerebellar degeneration, and extensive tumor screening in the patient has remained negative. Whether the anti-Ri antibodies in our index patient play a primary pathogenic role, or whether they are a secondary phenomenon caused by an unusual epitope presentation in the context of a neurodegenerative process, remains unresolved. Also, we can only speculate whether the presence of antiRi antibodies, at least in part, may have contributed to the phenotypic diversity between mother and daughter.
This report also raises important therapeutic considerations. Therapeutic interventions in other families harboring the R1668W mutation have not been described [6] . In our index patient and her mother, treatment with acetazolamide was ineffective for the episodic neurological symptoms and even exacerbated baseline cerebellar symptoms. By contrast, the calcium channel antagonist flunarizine was effective in controlling episodic symptoms without worsening of progressive symptoms. Successful treatment with flunarizine was previously described in a boy suffering from periodic ataxia without any sign of progressive cerebellar disease; however, this report appeared before the genetic characterization of EA2, and whether this boy had a mutation in CACNA1A cannot be determined [13] . Our experience with the index patient in this report compels us to propose that flunarizine be considered in EA patients who do not respond to acetazolamide. A different effect of the drugs on specific channel kinematics seems likely.
In conclusion, we confirm that CACNA1A mutations are associated with considerable phenotypic variability, even within family members harboring the same mutation. Further studies will be necessary to elucidate the basis of this phenotypic variability of CACNA1A mutations.
